Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/13/2018 08/14/2018 08/15/2018 08/16/2018 08/17/2018 Date
175.05(c) 175.93(c) 173(c) 174.96(c) 176.08(c) Last
810 394 566 678 907 510 732 505 965 416 Volume
+0.13% +0.50% -1.67% +1.13% +0.64% Change
More quotes
Financials (USD)
Sales 2018 3 003 M
EBIT 2018 1 044 M
Net income 2018 789 M
Finance 2018 2 701 M
Yield 2018 -
Sales 2019 3 533 M
EBIT 2019 1 338 M
Net income 2019 911 M
Finance 2019 3 744 M
Yield 2019 -
P/E ratio 2018 57,03
P/E ratio 2019 49,78
EV / Sales2018 14,1x
EV / Sales2019 11,7x
Capitalization 44 999 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
08/16VERTEX PHARMACEUTICALS : Awards Two College Students Full Scholarships to the Un..
BU
08/16RESTORBIO : Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
AQ
08/16RESTORBIO : Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
AQ
08/15VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® (ivacaftor) as First and Only Me..
PU
08/15VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® (ivacaftor) as First and Only Me..
BU
08/15VERTEX PHARMACEUTICALS : Kalydeco Approved for Kids 12-23 Months with Cystic Fib..
AQ
08/14VERTEX PHARMACEUTICALS : Amid pricing spat with U.K. government, Vertex won`t as..
AQ
08/14VERTEX PHARMACEUTICALS : NICE suspends review of Vertexs Symkevi for cystic fibr..
AQ
08/14VERTEX PHARMACEUTICALS : VRTX - FDA Approves ORKAMBI as First Medicine to Treat ..
AQ
08/11VERTEX PHARMACEUTICALS : NICE suspends review of Vertex`s Symkevi
AQ
More news
Sector news : Bio Therapeutic Drugs
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
03:23aHe’s from the shadowlands of the conservative establishment, but it was in a .. 
08/16An 8-year-old boy puts Vertex on the defensive about the price of its medicin.. 
08/16We launched the Vertex Discovery Camp with to show kids how much fun can b..
4
08/16Vertex cystic fibrosis drug gets expanded approval for use in infants: U.S. h.. 
08/16Traders Sell Vertex Pharmaceuticals $VRTX on Strength $VRTX  
More tweets
Qtime:134
News from SeekingAlpha
08/17Australia OKs reimbursement for Vertex's Orkambi 
08/15FDA OKs expanded use for Vertex Pharma's Kalydeco 
08/13VERTEX PHARMA : Analysts Say Buy This 'Growth Champion' 
08/13CRISPR First Look At June 2018 Updates 
08/13VERTEX PHARMACEUTICALS : Analysts Say Buy This 'Growth Champion' 
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 197 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian Frederick Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS16.75%44 999
GILEAD SCIENCES1.79%100 220
REGENERON PHARMACEUTICALS-0.45%38 873
NEUROCRINE BIOSCIENCES, INC.47.73%10 514
GENMAB2.24%9 810
BLUEBIRD BIO INC-11.29%8 449